Dr. med. Lars Fransecky
Facts
Phone:
+49-431-500-62239
E-Mail:
lars.fransecky[at]uksh.de
Affiliations:
University Medical Centre Schleswig-Holstein (UKSH), Campus Kiel
Address:
Arnold-Heller-Str.3, 24105 Kiel
Curriculum Vitae
Education/Training
| Since 2019 | Senior Attending Physician, Dept. of Hematology and Oncology, Christian-Albrechts-University Kiel, Medical Center Schleswig-Holstein, Campus Kiel, Germany |
| 2009-2019 | Resident, Charite, University Medicine Berlin, Germany |
| 2009 | Dr. med. (Thesis in medicine), Technical University of Dresden |
| 2002-2009 | Medical School, Technical University of Dresden, Germany Medical School, Universidad de Cantabria, Santander, Spain |
Research Experience/ Academic Appointments
| 2022 | Principal Investigator of an investigator-initiated trial of the German Multicenter Study Group of acute lymphoblastic leukemia: BLIVEN-ALL – An open-label, phase I/II study of Venetoclax in addition to Blinatumomab immunotherapy in adult patients with relapsed/refractory B cell precursor acute lymphoblastic leukemia (BCP-ALL) |
| Since 2022 | Primary Investigator of Deutsche Krebshilfe Grant: Co-targeting of independent apoptosis pathways by Venetoclax and Blinatumomab to overcome treatment resistance in B-cell precursor acute lymphoblastic leukemia |
| Since 2021 | Member of the Steering Committee of Study Alliance Leukemia (SAL) |
| 2009-2019 | Post-doctoral fellow, Charite, University Medicine Berlin, Germany |